jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 15, 2025

June. 05, 2026

jRCT2033240611

Open-Label, Dose Escalation, Single-dose Study of RV-001 in Subjects with Retinitis Pigmentosa (Phase I/II)

Phase I/II Study for RV-001

Katada Yusaku

Restore Vision Inc.

Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo

+81-90-5068-2405

chiken@restore-vis.com

Katada Yusaku

Restore Vision Inc.

Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo

+81-90-5068-2405

chiken@restore-vis.com

Recruiting

Feb. 01, 2025

45

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

18 years old and up at the time of ICF signature

Diagnosis of non-syndromic Retinitis Pigmentosa

Diagnosed with an inherited retinal degenerative disease other than non-syndromic Retinitis Pigmentosa or systemic symptoms, such as hearing loss.

Prior receipt of any genetic, cell-based or optogenetic therapy for Retinitis Pigmentosa, or prior participation in clinical trials for such therapies.

18age old over
No limit

Retinitis Pigmentosa

Administration of investigational product

Dose-Limiting Toxicity

Restore Vision Inc.
Keio University Hospital Institutional Review Board
35 Shinanomachi, Shinjuku-ku, Tokyo
Approval

Dec. 27, 2024

Kobe City Medical Center General Hospital Institutional Review Board
2-1-1, Minatojima-minamimachi, Chuo-ku, Kobe-city, Tokyo
Approval

Dec. 27, 2024

No

None

History of Changes

No Publication date
3 June. 05, 2026 (this page) Changes
2 Jan. 27, 2025 Detail Changes
1 Jan. 15, 2025 Detail